The monoclonal antibody bavituximab significantly shrank resistant human prostate tumors in mice when added to a standard regimen of androgen deprivation and docetaxel (Taxotere), according to researchers at the University of Texas Southwestern Medical Center in Dallas.
“These exciting results mimic the real-life situation facing many prostate cancer patients whose disease is failing to respond to the standard combination of androgen deprivation and chemotherapy drugs such as docetaxel,” said senior author Philip Thorpe, PhD.
Read full story in Urology Times
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment